Clinical Trials Logo

Dermatomyositis clinical trials

View clinical trials related to Dermatomyositis.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06438679 Enrolling by invitation - Dermatomyositis Clinical Trials

3T Therapy in the Treatment of MDA5-positive Dermatomyositis

Start date: March 19, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to learn if a combination of tacrolimus, tafocitinib and thalidomide (3T therapy) works to treat severe MDA5 positive dermatomyositis in adults. It will also learn about the safety of 3T therapy. The main questions it aims to answer are: Does 3T therapy prolong the overall survival time of MDA5 positive dermatomyositis? What medical problems do participants have when taking 3T therapy? Participants will: Take 3T therapy every day for 12 months Visit the clinic once every 2 weeks for checkups and tests

NCT ID: NCT05495321 Enrolling by invitation - Dermatomyositis Clinical Trials

Interleukin-2 on Active Dermatomyositis

Start date: December 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this paper is to explore the effect of low-dose IL-2 on refractory dermatomyositis and immunological indexes.

NCT ID: NCT01637064 Enrolling by invitation - Dermatomyositis Clinical Trials

Dermatomyositis and Polymyositis Registry

ADAPT
Start date: April 2013
Phase: N/A
Study type: Observational

By creating a registry, physicians will have the opportunity to understand the clinical outcomes of Myositis patients treated with Acthar. Despite the availability of clinical exams, muscle biopsies, and other testing, it is surmised that there may be a more important classification of myositis that physicians are not diagnosing which could possibly lead to improper treatment due to inaccurate diagnosis. There may be several types of immune and inflammatory myositis (IIM) that do not fit well into the typical sub classifications of myositis.